Our programs target RAF/MEK inhibition, focal adhesion kinase (FAK), and phosphoinositide 3-kinase (PI3K-delta/gamma). Preclinical research has shown that these targets are important for both cancer cell survival and the tumor microenvironment that supports the cancer cells.